RxDoctor Payments Data

Sam Kalioundji, MD

Interventional Cardiology · Northridge, CANPI 1619129426

Payments from drug & device makers

$36,994in general payments, 2019–2025

Across 723 payments — averaging $51.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$19K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
  • Boston Scientific$2K
  • Abiomed$2K
  • Medtronic$2K
  • Novartis$2K
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$10,07127%
  • Speaking & faculty fees$1,5004%
  • Travel & lodging$5,40615%
  • Food & beverage$19,92954%
  • Education$880%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,994 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$5,787,229
Medicare patients
2,417
Services billed
51,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban654$744,940
EntrestoSacubitril/Valsartan433$522,198
XareltoRivaroxaban242$243,157
BrilintaTicagrelor96$74,512
FarxigaDapagliflozin Propanediol66$66,604
Repatha SureclickEvolocumab54$57,786
JardianceEmpagliflozin39$39,713
VerquvoVericiguat32$35,595
OzempicSemaglutide18$19,115
VascepaIcosapent Ethyl34$15,444
Praluent PenAlirocumab14$14,767
DapagliflozinDapagliflozin Propanediol21$13,450
ClopidogrelClopidogrel Bisulfate1,154$12,194
Atorvastatin Calcium1,014$10,621
Nifedipine ErNifedipine225$9,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$231$744,940654 claims
NovartisEntresto$1,623$522,198433 claims
Johnson & JohnsonXarelto$917$243,157242 claims
AstraZenecaBrilinta, Farxiga$272$141,116162 claims
Boehringer IngelheimJardiance$305$39,71339 claims
MerckVerquvo$344$35,59532 claims
Novo NordiskOzempic$109$19,11518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Northridge

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →